Biogen Inc. (NASDAQ:BIIB) Receives Average Rating of “Hold” from Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have been assigned a consensus rating of “Hold” from the twenty-eight research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $209.7692.

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Sunday, February 8th. Guggenheim boosted their price target on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Mizuho boosted their price target on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $185.00 to $225.00 in a research note on Wednesday. Finally, BMO Capital Markets boosted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research note on Friday, February 6th.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $190.07 on Friday. The company has a 50 day moving average of $185.53 and a 200 day moving average of $174.73. The stock has a market cap of $27.89 billion, a P/E ratio of 21.57, a P/E/G ratio of 2.48 and a beta of 0.16. Biogen has a 12 month low of $115.25 and a 12 month high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the company earned $3.44 EPS. The business’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts forecast that Biogen will post 15.82 EPS for the current fiscal year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy from Neutral and raised its price target to $225, citing a “slew of pipeline catalysts” across the next 12–15 months (readouts and commercialization milestones that could meaningfully re‑rate the stock). Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Positive Sentiment: Biogen secured Greater China rights to felzartamab (the immune‑disease antibody) — the deal gives Biogen another late‑stage asset as global phase IIIs progress and supports commercial optionality in a large market. BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
• Positive Sentiment: Biogen announced a strategic deal with TJ Biopharma (transaction details reported to expand Biogen’s pipeline/partnership footprint), which traders viewed as supportive of near‑term momentum. Biogen Zooms on Deal with TJ Biopharma
• Neutral Sentiment: Analyst commentary and aggregator coverage (TipRanks/press summaries) amplify the UBS thesis (mentions of Apellis acquisition and valuation discount), reinforcing the bullish narrative but largely repeating the same catalysts. Biogen: Underappreciated Late‑Stage Pipeline, Apellis Acquisition…
• Negative Sentiment: HSBC maintains a Reduce rating and a $150 target, publishing conservative multi‑year EPS forecasts — a counterpoint to UBS that highlights downside risk if pipeline readouts or commercial execution disappoint. MarketBeat Biogen coverage (HSBC estimates)
• Negative Sentiment: A Zacks earnings preview warns Q1 revenue/earnings may decline vs. year‑ago levels, reminding investors of near‑term volatility and execution risk ahead of upcoming results. Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biogen

A number of hedge funds have recently made changes to their positions in BIIB. Reflection Asset Management bought a new stake in shares of Biogen in the 4th quarter worth approximately $25,000. WPG Advisers LLC lifted its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the last quarter. Accredited Wealth Management LLC lifted its holdings in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the last quarter. First Horizon Corp bought a new stake in shares of Biogen in the 4th quarter worth approximately $30,000. Finally, WFA of San Diego LLC bought a new stake in shares of Biogen in the 2nd quarter worth approximately $32,000. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.